Science: Amyloid protein lesion also can be the bane of tumor

Scientists at the Flanders Institute for Biotechnology (FIB) in Belgium have published a study releasing a patent called Pept-in in the world-renowned scientific journal Science. This patent was developed through recombinant human proteins and can simulate Alzheimer's disease Amyloid formation mechanism and make use of amyloid polymerization properties to make the disease protein of tumor and other diseases assemble and lose function, thus achieving therapeutic purposes. This represents a new idea of drug development and may be able to bring targeted new treatment of a variety of diseases including cancer.

Amyloid protein is a ubiquitous protein found in our daily foods, such as boiled eggs and beer foams. It has also been shown to be associated with Alzheimer's disease, multiple sclerosis, Parkinson's disease, glaucoma and other diseases. In particular, a typical pathological change of Alzheimer's disease is amyloidogenic amyloidosis in the brain to form amyloid plaques. With regard to amyloidosis related to medical research and drug development, the current mainstream idea is to inhibit the protein to treat diseases, rather than the use of this protein. There has been a significant capital injection into the development of new drugs that target amyloidogenic targets such as beta amyloidosis and Tau protein.

Amyloid formation seems to imply a negative pathogenic signal. However, research teams led by Prof. Frederic Rousseau and Professor Joost Schymkowitz of the VIB Institute have used these substances to form tumors and attack many diseases.

They used their own development of Pept-in patented technology to design and synthesize a vascin called amyloidogenic material (a characteristic amyloid protein structure of short-chain peptide sequence). The molecule has to promote amyloidosis which can rapidly penetrate the tumor cell membrane and promote the tumor cells on the vascular endothelial growth factor receptor 2 (VEGFR2) protein cohesive degeneration and lose their function. VEGFR2 is an important molecule to promote the survival of tumor growth. It means that the inactivation of cancer can inhibit the therapeutic effect.

"This method allows the surface protein of the tumor to condense. It is just like a tumor-like spider web-like dragnet traps tumor to limit its growth," Professor Rousseau said. He is convinced that using of Pept-in patented technology and aimed at the key disease for many diseases protein, they can design and synthesize the corresponding polymer molecules (amyloid protein structure of the characteristics of short-chain peptide sequence) to promote the pathogenic target protein to enhance cohesion and then fight many diseases. Because Pept-in patented technology makes use of the principle of amyloid formation to apply it to almost any target protein aggregation process. In the future, it can’t only be used to develop anti-cancer therapy, but also can be used against drug-resistant bacterial infection.

"In the next few years, our team will focus on using this technology to benefit more patients," Professor Schymkowitz said at the press conference. Flarebio offers recombinant proteins of good quality such as recombinant PIGR at great prices.